{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-24-000019","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.758655+00:00","generated_at":"2026-06-07T02:18:04.745004+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ivonescimab Phase II shows 64.8% 24-month OS in 1L squamous NSCLC; cash ≥$186M","bullets":["Phase II AK112-201: 24-month OS rate 64.8% in 63 1L squamous NSCLC patients; median OS not reached after 21.0 months follow-up.","In 19 2L+ EGFRm NSCLC patients (post-TKI), median OS 22.5 months; 12-month OS rate 74%.","Near-term catalysts: Chinese NDA decision for AK112-301 (Q2 2024) and interim analysis of AK112-303 vs. pembrolizumab (Q2 2024).","Preliminary cash, cash equivalents, and short-term investments at least $186M as of Dec 31, 2023 (unaudited).","Two global Phase III trials ongoing: HARMONi (EGFRm NSCLC) and HARMONi-3 (1L squamous NSCLC vs. pembrolizumab)."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-24-000019","json":"https://secwatch.observer/filing/0001599298-24-000019.json","markdown":"https://secwatch.observer/filing/0001599298-24-000019.md","text":"https://secwatch.observer/filing/0001599298-24-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000019/0001599298-24-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929824000019/smmt-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:18:04.745004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}